Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate
Palisade Bio, Inc. recently announced the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the company’s novel, locally activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).
Once issued, the allowed patent titled, Gut Microbiota-Activated PDE4 Inhibitor Prodrug, will cover claims on the composition of matter for PALI-2108 in China with a base patent term currently extending into 2045, subject to extension to account for time required to fulfill requirements for regulatory approval.
“Strengthening the global intellectual property portfolio around PALI-2108 remains a priority as we continue advancing this first-in-class therapy for FSCD and UC,” said J.D. Finley, Chief Executive Officer of Palisade Bio. “This Notice of Allowance in China bolsters our ability to protect long-term value in one of the world’s largest and fastest-growing pharmaceutical markets, further supporting both our clinical and strategic objectives. We remain highly confident in the potential of PALI-2108 and are diligently executing on multiple near-term clinical milestones and expected data readouts in the next 12-18 months, each of which, if successful, would represent a major value inflection point.”
The company is currently evaluating PALI-2108 in a Phase 1b/2a clinical trial for the treatment of FSCD and UC. For more information about the Phase 1a/b clinical study, visit clinicaltrials.gov and reference identifier NCT06663605.
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company believes by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, visit www.palisadebio.com.
Total Page Views: 831
